About 40-70% of drug molecules in the clinical development pipeline suffer from one of\neither low aqueous solubility, poor absorption, or extremely low bioavailability. Approximately 75%\nof the world population relies on traditional therapies and therefore there has been a growing interest\nin the utilization of natural compounds. Zerumbone is one such natural compound, classified as a\nsesquiterpenoid that is extracted from the essential volatile oils of rhizomes from Zingiber zerumbet.\nIt possesses strong antitumor, antioxidant, antimicrobial, and anti-inflammatory activity. However,\ndespite promising preclinical studies demonstrating the therapeutic utility of zerumbone, its clinical\ndevelopment has been limited due to its low aqueous solubility, poor absorption, or associated low\nbioavailability. Multiple reviews demonstrating the pharmacological effects of zerumbone for various\ndiseases have been published. However, to our knowledge, no review demonstrates the various\nformulation strategies developed to overcome the biopharmaceutical challenges of zerumbone.\nThe purpose of this review is to provide a comprehensive perspective on zerumbone as a molecule for\nformulation development. A section related to pharmacokinetics, toxicity, and patents of zerumbone\nis included. This review provides the importance of developing novel formulations of zerumbone\nto overcome its biopharmaceutical challenges thereby advance its potential in the treatment of\nvarious diseases.
Loading....